PMI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Picard Medical Inc (PMI) is not a good buy for a beginner, long-term investor at this time. The stock is under legal scrutiny with multiple class action lawsuits, and its financial performance, while showing some improvement in revenue and net income, remains weak with negative EPS and gross margins. Technical indicators are mixed, with bearish moving averages and no strong trading signals. The absence of significant positive catalysts and the presence of legal risks make this stock unsuitable for the user's investment profile.
The MACD is positive and expanding, indicating some bullish momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level (R1: 1.293) in pre-market, with a pre-market price of 1.29 and a -2.33% change, suggesting potential downward pressure. Key support levels are at 0.995 and 0.903.
Revenue increased by 34.73% YoY in Q3 2025, and net income improved by 51.34% YoY.
Multiple class action lawsuits alleging securities fraud, declining gross margins (-85.67% YoY), and negative EPS (-0.14). No significant hedge fund or insider trading activity. The stock has a low probability of significant short-term gains based on historical candlestick patterns.
In Q3 2025, revenue increased to $1,187,000 (up 34.73% YoY), net income improved to -$10,426,000 (up 51.34% YoY), and EPS improved to -0.14 (up 40.00% YoY). However, gross margin dropped significantly to -10.95% (down -85.67% YoY), indicating operational inefficiencies.
No analyst rating or price target changes available.
